ArticleCureus2025
Chrono-Immune Neuropathy During PD-1 Blockade: A Report of a Fatal Case and Hypothesis on Circadian Modulation of Neurotoxicity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors can cause a wide spectrum of immune-related adverse events, including rare but severe neurological complications. This report describes a fatal case of progressive immune-mediated neuropathy in a melanoma patient treated with PD-1 blockade, in whom worsening neuropathic pain and functional decline coincided with irregular, non-aligned timing of immunotherapy infusions. PET-CT imaging, MRI, and laboratory testing excluded metastatic, infectious, metabolic, and paraneoplastic causes. Longitudinal evaluation revealed fluctuations in inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), with peaks occurring shortly after late-afternoon infusions. Earlier infusions were associated with fewer symptoms. Although causality cannot be established from a single case, this temporal association raises the possibility that circadian desynchronization may amplify immune activation and contribute to neurotoxicity. Based on these observations, the concept of "Chrono-Immune Neuropathy" is proposed, suggesting that disrupted temporal regulation of treatment may influence the severity of neurologic immune-related adverse events. This case highlights the potential importance of consistent, circadian-aware scheduling in immunotherapy and supports further investigation into time-of-day-sensitive treatment strategies aimed at reducing toxicity and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.